Related Experiment Video
Updated: Oct 2, 2026

Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
Chronic kidney disease and intravenous thrombolysis in acute stroke: A systematic review and meta-analysis
Jin-Man Jung1, Hyun Jung Kim2, Hyeongsik Ahn2
1Department of Neurology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Republic of Korea.
Insights
Patients with chronic kidney disease (CKD) face increased risks of symptomatic hemorrhage and mortality after receiving intravenous thrombolytics for stroke. This meta-analysis highlights the significant impact of CKD on stroke treatment outcomes.
Area of Science:
- Nephrology
- Neurology
- Cardiovascular Medicine
Background:
- The relationship between chronic kidney disease (CKD) and bleeding complications or outcomes in patients receiving intravenous thrombolytics remains debated.
- Acute stroke treatment involves balancing reperfusion benefits against bleeding risks.
Purpose of the Study:
- To investigate the association between CKD and symptomatic intracerebral hemorrhage (ICH) or clinical outcomes in acute stroke patients treated with IV tissue plasminogen activator (tPA).
Main Methods:
- A systematic literature search identified eligible observational studies with adjusted analyses.
- Study quality was assessed, and a meta-analysis was performed.
- Primary outcome: symptomatic ICH. Secondary outcomes: 3-month functional status, 3-month mortality, and any ICH.
Main Results:
- Seven studies comprising 7168 patients were analyzed; 27.9% had CKD.
- CKD patients showed a higher risk of symptomatic ICH (OR 1.56) and mortality (OR 1.70).
- An increased risk of poor 3-month functional outcome was observed in CKD patients; no significant association with any ICH was found.
Conclusions:
- Chronic kidney disease is associated with significantly higher risks of symptomatic hemorrhagic complications and adverse clinical outcomes after IV tPA administration in acute stroke.
- These findings underscore the importance of considering renal function in stroke management and risk stratification.
Background:
The association between chronic kidney disease (CKD) and hemorrhagic complications or clinical outcomes in patients treated with intravenous (IV) thrombolytic agents is controversial.
Methods:
We searched multiple databases for studies on the association between CKD and symptomatic intracerebral hemorrhage (ICH) and/or clinical outcomes in acute stroke patients treated with IV tissue plasminogen activator (tPA). Observational studies that evaluated the association between CKD and outcomes after adjusting for other confounding factors were eligible. We assessed study quality and performed a meta-analysis. The main outcome was symptomatic ICH. The secondary outcomes were poor functional status at 3 months using the modified Rankin Scale, mortality at 3 months, and any ICH.
Results:
Seven studies were selected based on our eligibility criteria. Of 7168 patients treated with IV tPA, 2001 (27.9%) had CKD. Patients with CKD had a higher risk of symptomatic ICH and mortality [pooled odds ratio (OR) 1.56, 95% confidence interval (CI) 1.05-2.33 and pooled OR 1.70, 95% CI 1.03-2.81, respectively]. Patients with CKD were likely to have an increased risk of poor outcome at 3 months. There was no significant association between CKD and any ICH.
Conclusions:
Chronic kidney disease may significantly affect symptomatic hemorrhagic complications and poor clinical outcomes following administration of IV tPA.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Acute Kidney Injury I: Introduction
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury V: Interprofessional Care
Chronic Kidney Disease III: Interprofessional Care

